BR112022026521A2 - Vetor viral, célula isolada, composição farmacêutica, uso de um vetor viral, método, e, método para prevenir ou tratar uma doença renal - Google Patents
Vetor viral, célula isolada, composição farmacêutica, uso de um vetor viral, método, e, método para prevenir ou tratar uma doença renalInfo
- Publication number
- BR112022026521A2 BR112022026521A2 BR112022026521A BR112022026521A BR112022026521A2 BR 112022026521 A2 BR112022026521 A2 BR 112022026521A2 BR 112022026521 A BR112022026521 A BR 112022026521A BR 112022026521 A BR112022026521 A BR 112022026521A BR 112022026521 A2 BR112022026521 A2 BR 112022026521A2
- Authority
- BR
- Brazil
- Prior art keywords
- viral vector
- treat
- pharmaceutical composition
- prevent
- kidney disease
- Prior art date
Links
- 239000013603 viral vector Substances 0.000 title abstract 6
- -1 ISOLATED CELL Substances 0.000 title abstract 2
- 208000017169 kidney disease Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000002773 nucleotide Substances 0.000 abstract 2
- 125000003729 nucleotide group Chemical group 0.000 abstract 2
- 210000000557 podocyte Anatomy 0.000 abstract 2
- 102000000989 Complement System Proteins Human genes 0.000 abstract 1
- 108010069112 Complement System Proteins Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000002463 transducing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Image Analysis (AREA)
- Devices For Executing Special Programs (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2010009.5A GB202010009D0 (en) | 2020-06-30 | 2020-06-30 | Vector |
| PCT/GB2021/051668 WO2022003357A1 (en) | 2020-06-30 | 2021-06-30 | Vector |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022026521A2 true BR112022026521A2 (pt) | 2023-01-31 |
Family
ID=71949697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022026521A BR112022026521A2 (pt) | 2020-06-30 | 2021-06-30 | Vetor viral, célula isolada, composição farmacêutica, uso de um vetor viral, método, e, método para prevenir ou tratar uma doença renal |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230175016A1 (https=) |
| EP (1) | EP4172345A1 (https=) |
| JP (1) | JP2023536008A (https=) |
| KR (1) | KR20230056658A (https=) |
| CN (1) | CN115997025A (https=) |
| AU (1) | AU2021300616A1 (https=) |
| BR (1) | BR112022026521A2 (https=) |
| CA (1) | CA3183830A1 (https=) |
| GB (1) | GB202010009D0 (https=) |
| IL (1) | IL299505A (https=) |
| MX (1) | MX2022016101A (https=) |
| WO (1) | WO2022003357A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202003618D0 (en) | 2020-03-12 | 2020-04-29 | Univ Bristol | Gene Therapy |
| CA3182800A1 (en) | 2020-06-14 | 2021-12-23 | Vertex Pharmaceuticals Inc. | Complement factor i-related compositions and methods |
| GB202217332D0 (en) * | 2022-11-18 | 2023-01-04 | Univ Bristol | Methods |
| EP4410988A1 (en) * | 2023-01-31 | 2024-08-07 | Universitätsklinikum Hamburg-Eppendorf | An aav2-vector variant for targeted transfer of genes |
| WO2024178007A1 (en) * | 2023-02-21 | 2024-08-29 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Mafb promoter for gene therapy for diabetes |
| GB202304841D0 (en) * | 2023-03-31 | 2023-05-17 | Purespring Therapeutics Ltd | Promoter |
| CN121013858A (zh) * | 2023-04-27 | 2025-11-25 | 俄勒冈健康与科学大学 | 靶向肾脏的aav衣壳及其使用方法 |
| GB202414499D0 (en) * | 2024-10-02 | 2024-11-13 | Purespring Therapeutics Ltd | Methods |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT904392E (pt) | 1996-10-17 | 2001-06-29 | Oxford Biomedica Ltd | Vectores retrovirais |
| WO2005012351A2 (en) * | 2003-08-01 | 2005-02-10 | The Brigham And Women's Hospital, Inc. | Novel functions for decay accelerating factor (daf) in inflammation |
| US7745389B2 (en) * | 2005-02-14 | 2010-06-29 | University Of Iowa Research Foundation | Methods for treatment of age-related macular degeneration |
| EP2730282A1 (en) * | 2007-11-08 | 2014-05-14 | The General Hospital Corporation | Methods and compositions for the treatment of proteinuric diseases |
| ES2857773T5 (es) * | 2011-08-24 | 2024-06-04 | Univ Leland Stanford Junior | Nuevas proteínas de la cápside de AAV para la transferencia de ácidos nucleicos |
| GB201403684D0 (en) * | 2014-03-03 | 2014-04-16 | King S College London | Vector |
| CN108291216B (zh) * | 2015-09-24 | 2022-09-16 | 宾夕法尼亚州大学信托人 | 用于治疗补体介导的疾病的组合物和方法 |
| JP7222075B2 (ja) * | 2018-09-13 | 2023-02-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｃ３糸球体症のモデルとしての補体因子ｈ遺伝子ノックアウトラット |
-
2020
- 2020-06-30 GB GBGB2010009.5A patent/GB202010009D0/en not_active Ceased
-
2021
- 2021-06-30 AU AU2021300616A patent/AU2021300616A1/en active Pending
- 2021-06-30 KR KR1020237003243A patent/KR20230056658A/ko active Pending
- 2021-06-30 IL IL299505A patent/IL299505A/en unknown
- 2021-06-30 CN CN202180046691.7A patent/CN115997025A/zh active Pending
- 2021-06-30 CA CA3183830A patent/CA3183830A1/en active Pending
- 2021-06-30 BR BR112022026521A patent/BR112022026521A2/pt unknown
- 2021-06-30 EP EP21748644.8A patent/EP4172345A1/en active Pending
- 2021-06-30 JP JP2023523681A patent/JP2023536008A/ja active Pending
- 2021-06-30 US US18/011,592 patent/US20230175016A1/en active Pending
- 2021-06-30 WO PCT/GB2021/051668 patent/WO2022003357A1/en not_active Ceased
- 2021-06-30 MX MX2022016101A patent/MX2022016101A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021300616A1 (en) | 2023-01-19 |
| CN115997025A (zh) | 2023-04-21 |
| KR20230056658A (ko) | 2023-04-27 |
| GB202010009D0 (en) | 2020-08-12 |
| CA3183830A1 (en) | 2022-01-06 |
| WO2022003357A1 (en) | 2022-01-06 |
| EP4172345A1 (en) | 2023-05-03 |
| JP2023536008A (ja) | 2023-08-22 |
| US20230175016A1 (en) | 2023-06-08 |
| MX2022016101A (es) | 2023-06-01 |
| IL299505A (en) | 2023-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022026521A2 (pt) | Vetor viral, célula isolada, composição farmacêutica, uso de um vetor viral, método, e, método para prevenir ou tratar uma doença renal | |
| BR112022008858A2 (pt) | Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer | |
| BR112022009895A2 (pt) | Construtos de terapia de gene de microdistrofina e usos dos mesmos | |
| BR112021022796A2 (pt) | Inibidores de inflamassoma de nlrp3 | |
| BR112021010715A2 (pt) | Pirazolopirimidinas substituídas e purinas substituídas e seu uso como inibidores de protease de processamento ubiquitina-específica 1 (usp1) | |
| BR112017028205A2 (pt) | molécula de rna, vetor, célula hospedeira, composição farmacêutica, kit, e, uso de uma ou mais utrs. | |
| BR112022000503A2 (pt) | Compostos úteis para tratar infecções por vírus influenza | |
| BR112021024553A2 (pt) | Molécula de ligação específica para cd73 e uso de molécula de ligação | |
| BR112018012179A2 (pt) | adenovírus de grupo b que codifica um anticorpo ou fragmento de complexo anti-tcr | |
| BR112019011860A2 (pt) | proteína de fusão insulina-fc, sequência de ácido nucleico recombinante que codifica a mesma, vetor, célula eucariótica modificada, kit e método para tratar ou prevenir o diabetes autoimune | |
| BR112015016793A2 (pt) | compostos de tiazolacarboxamidas e piridinacarbo-xamida úteis como inibidores de quinase pim | |
| BR112017023171A2 (pt) | adenovírus oncolítico que codifica proteína b7 | |
| BR112012024382A2 (pt) | agentes que induzem apoptose para o tratamento de câncer e doenças imunes e autoimunesças | |
| BR112018072545A2 (pt) | inibidores da arginase e suas aplicações terapêuticas | |
| BR112016028818A2 (pt) | composição farmacêutica, métodos de tratamento de uma doença ou condição, de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase e de inibição de reações imunes excessivas ou destrutivas ou crescimento ou proliferação de células cancerosas, kit, composto, sal, isômero, ou uma mistura farmaceuticamente aceitável do mesmo, e, uso de um composto, um sal, isômero, ou uma mistura farmaceuticamente aceitável do mesmo. | |
| BR112013011184A2 (pt) | composições e métodos para tratamento de mielofibrose | |
| BR112016028819A2 (pt) | composição farmacêutica, métodos para tratar uma doença ou condição em um ser humano e para inibir a atividade de um polipeptídeo de fosfatidilinositol 3-quinase e reações imunológicas excessivas ou destrutivas ou o crescimento ou a proliferação de células cancerosas, kit, composto, sal farmaceuticamente aceitável, isômero ou mistura dos mesmos, e, uso de um composto, sal farmaceuticamente aceitável ou mistura dos mesmos. | |
| EA202290001A1 (ru) | Векторы aav с промотором миелинового белка ноль и их применение для лечения заболеваний, связанных со шванновскими клетками, таких как болезнь шарко-мари-тута | |
| BR112022000724A2 (pt) | Proteínas de capsídeo de aav modificado para tratamento de doença artrítica | |
| BRPI0913291A2 (pt) | composto, pró-droga, medicamento, métodos para diminuir a proteína 4 ou tratamento de diabete em um mamífero, e, uso do composto | |
| BR112015030355A8 (pt) | uso de uma proteína ou um polipeptídeo de adenilil ciclase tipo 6 (ac6) incompetente com a adenosina monofosfato cíclico (incompetente com camp) ou um gene ou ácido nucléico que codifica ac6mut, e, formulação | |
| BR112021017467A2 (pt) | Receptores de células t e métodos de uso dos mesmos | |
| BR112023021231A2 (pt) | Produtos e composições | |
| BR112021023473A2 (pt) | Vetores de terapia genética para osteopetrose maligna infantil | |
| Yeon et al. | Phosphatidylinositol‐3‐kinase and Akt are required for RIG‐I‐mediated anti‐viral signalling through cross‐talk with IPS‐1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: THE UNIVERSITY OF BRISTOL (GB) ; PURESPRING THERAPEUTICS LIMITED (GB) ; SYNCONA IP HOLDCO (3) LIMITED (GB) |
|
| B25A | Requested transfer of rights approved |
Owner name: THE UNIVERSITY OF BRISTOL (GB) ; SYNCONA IP HOLDCO (3) LIMITED (GB) |